AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$TNGX

Newcomb Jessica sold $199K of TNGX

Newcomb Jessica (Principal Accounting Officer) sold 8,200 shares of Tango Therapeutics, Inc. (TNGX) at an average of $24.22 ($22.80–$25.17, $0.20M total) across 3 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Newcomb Jessica
Published Sep 24, 2026, 11:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 12:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNGX
Neutral
medium confidence
Mentioned
$TNGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNGXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to move the stock significantly.

02

Market read

Minor insider sale with limited trading impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 5/10Timing: filing date 2026-09-24

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$TNGXNeutralMedium confidence
Context

Principal Accounting Officer sold 8,200 shares for $198.6K via a 10b5-1 plan, reducing her stake to 59,121 shares.

Expected impact

Potential slight downward pressure in the short term, likely limited to a few basis points.

Evidence & confidence

A $199K sale by a senior officer is routine and below materiality thresholds; markets typically react modestly to such disclosures.

Market effects

Sector

No broader sector impact; the sale is company‑specific.

Regional

Limited to investors tracking Tango Therapeutics.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a strategic rebalancing rather than a lack of confidence.

Key entities

  • Officer
    Newcomb Jessica

    Principal Accounting Officer of Tango Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNGX insider trading history →

Related articles

OCT 23
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat, showing strong efficacy in pancreatic and lung cancers when combined with Revolution Medicines' (RVMD) RAS(ON) inhibitors. The combination achieved 82% and 80% response rates in pancreatic and lung cancer patients, respectively. Tango plans a global registrational study in 2027. TNGX shares fell 10.65% to $24.95 on Friday.

finance.yahoo.com2 min